---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-22-002261"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2022-06-01T23:59:59+00:00"
generated_at: "2026-06-25T05:27:26.886912+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Chemomab Director Joel Maryles to step down at 2022 AGM

## Summary
- Joel Maryles, Class I director, notified Chemomab on May 31, 2022 he will not seek re-election.
- Departure effective at the 2022 Annual General Meeting on June 7, 2022.
- Departure not due to any disagreement with the Company, management, board, or operations.

## SEC filing metadata
- accession: 0001178913-22-002261
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2022-06-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891322002261/0001178913-22-002261-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891322002261/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-22-002261
- JSON: https://secwatch.observer/filing/0001178913-22-002261.json
- Plain text: https://secwatch.observer/filing/0001178913-22-002261.txt

## Key facts
- Executive change
  Joel Maryles departed as Class I Director at Chemomab Therapeutics Ltd..
  - Action: not standing for re-election
  - Role: Class I Director
  source text: On May 31, 2022, Joel Maryles, a member of the Board of Directors (the “Board”) of Chemomab Therapeutics Ltd. (the “Company”), notified the Company that he will not stand for re-election at the Company’s 2022 Annual General Meeting of shareholders, to be held on June 7, 2022, and, accordingly, Mr. Maryles’ term as a Class I director will expire at the 2022 Annual General Meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534248/000117891322002261/0001178913-22-002261-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.